GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xcell Therapeutics Inc (XKRX:373110) » Definitions » Tax Provision

Xcell Therapeutics (XKRX:373110) Tax Provision : ₩0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Xcell Therapeutics Tax Provision?

Xcell Therapeutics's tax provision for the three months ended in Sep. 2024 was ₩0 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was ₩0 Mil.


Xcell Therapeutics Tax Provision Historical Data

The historical data trend for Xcell Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcell Therapeutics Tax Provision Chart

Xcell Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Provision
- - - - -

Xcell Therapeutics Quarterly Data
Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Provision Get a 7-Day Free Trial - - - - -

Xcell Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xcell Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
333, Yeongdong-daero, Gangnam-gu, Seoul, KOR, 06188
Xcell Therapeutics Inc operates as a research company engaged in development of regenerative medicines. The company is developing proliferation media for various animal cell types.

Xcell Therapeutics Headlines

No Headlines